1369796-75-7

Upstream product

• 1369796-74-6 6-(3-fluorophenoxy)hexan-1-ol 
• 4286-55-9 1-bromo-6-hexanol 
• 372-20-3 3-fluorophenol 

Downstream Products

• 1369796-76-8 7-(3-fluorophenoxy)-2-hydroxyheptanenitrile 
• 1369796-78-0 7-(3-fluorophenoxy)-2-hydroxyheptanoic acid 
• 1369796-81-5 N-((5-(4-(benzyloxy)phenyl)-1,3,4-oxadiazol-2-yl)methyl)-7-(3-fluorophenoxy)-2-hydroxyheptanamide 
• 1369796-77-9 C₁₄H₁₉FO₄ 
• 1369795-50-5 N-((5-(4-(benzyloxy)phenyl)-1,3,4-oxadiazol-2-yl)methyl)-7-(3-fluorophenoxy)-2-oxoheptanamide 
• 1383152-24-6 (2R,3R,4R,5S)-1-(6-(3-fluorophenoxy)hexyl)-2-(hydroxymethyl)piperidine-3,4,5-triol 

Relevant academic research and scientific papers

ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS

The present invention is directed to α-ketoamide derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by endothelial lipase, for example, cardiovascular disorders.

Design, synthesis, and biological evaluation of N-Alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection

We recently described the discovery of oxygenated N-alkyl deoxynojirimycin (DNJ) derivative 7 (CM-10-18) with antiviral activity against dengue virus (DENV) infection both in vitro and in vivo. This imino sugar was promising but had an EC50 against DENV in BHK cells of 6.5 μM, which limited its use in in vivo. Compound 7 presented structural opportunities for activity relationship analysis, which we exploited and report here. These structure-activity relationship studies led to analogues 2h, 2l, 3j, 3l, 3v, and 4b-4c with nanomolar antiviral activity (EC50 = 0.3-0.5 μM) against DENV infection, while maintaining low cytotoxicity (CC50 > 500 μM, SI > 1000). In male Sprague-Dawley rats, compound 3l was well tolerated at a dose up to 200 mg/kg and displayed desirable PK profiles, with significantly improved bioavailability (F = 92 α 4%).